The small molecule galunisertib, a selective inhibitor of the serine/threonine kinase of the TGF-β receptor type I (TGF-β RI) [14], reversed E-cadherin secretion in highly invasive HCC cell lines and increased the expression of E-cadherin on tumor cells [13]. Here, CDH1 is linked to hepatocellular carcinoma.